Anhui Fengyuan Pharmaceutical's (SHE:000153) unit, Bengbu Fengyuan Tushan Pharmaceutical, obtained approval from China's National Medical Products Administration for the marketing of vonoprazan fumarate, according to a Shenzhen bourse filing on Wednesday.
The chemical raw material was developed for the treatment of reflux esophagitis and Helicobacter pylori infection.